A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

Summary

This study is being done to test the safety and efficacy of the study drug LY3857210 for the treatment of diabetic peripheral neuropathic pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.

Timeline

Start

2022-11-14

Primary completion

2023-07-19

Completion

2023-08-01

Outcome

Missed primary endpoint

registry analysis (superiority test); 45 mg LY3857210 vs Placebo; Posterior Mean Difference 0.10 (95% CI -0.61 to 0.82) NCT05620576 ↗

Drugs

Indications